Skip to content
NewsBlazeAU – Lifestyle
Author:
Johnson & Johnson Innovative Medicine
Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)
September 29, 2026